These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25488880)

  • 1. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
    Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
    Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
    Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.
    Gao T; Liu J; Wu J
    Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34201096
    [No Abstract]   [Full Text] [Related]  

  • 5. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
    Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
    Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
    Latimer NR; Abrams KR; Amonkar MM; Stapelkamp C; Swann RS
    Oncologist; 2015 Jul; 20(7):798-805. PubMed ID: 26040620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
    Gil-Rojas Y; Lasalvia P; Hernández F; Castañeda-Cardona C; Castrillón-Correa J; Herrera D; Rosselli D
    Value Health Reg Issues; 2021 Dec; 26():182-190. PubMed ID: 34673349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.
    Trouiller JB; Nikolaidis GF; Macabeo B; Meyer N; Gerlier L; Schlueter M; Laramee P
    Eur J Health Econ; 2024 Jun; 25(4):641-653. PubMed ID: 37433888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
    Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
    Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
    Cai C; Yunusa I; Tarhini A
    JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.
    Curl P; Vujic I; van 't Veer LJ; Ortiz-Urda S; Kahn JG
    PLoS One; 2014; 9(9):e107255. PubMed ID: 25198196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
    Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
    Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
    Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.